Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Pomegranate Juice for PSA-only Prostate Cancer Recurrence

Name of the Trial

Phase III Randomized Study of Pomegranate Juice in Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiotherapy for Localized Prostate Cancer (UCLA-0507059-01). See the protocol summary.

Principal Investigators

Dr. Allan Pantuck
Dr. Allan Pantuck
Principal Investigator

Dr. Allan Pantuck and Dr. Arie Belldegrun, Jonsson Comprehensive Cancer Center at UCLA.

Why This Trial Is Important

Surgery and radiotherapy are common treatments for localized prostate cancer (cancer confined to the prostate gland). Following such treatments, doctors may monitor the blood level of a protein called prostate-specific antigen (PSA). An increase in PSA level may be an early indicator that prostate cancer has returned. Research has shown that the length of time it takes for a rising PSA level to double (called PSA doubling time) can be useful in predicting the risk of prostate cancer progression and death.

Currently, there is no standard treatment for men who have recurrent prostate cancer detected by an increase in PSA level only. Consequently, doctors want to develop treatments that can slow down or reverse increases in PSA without causing serious side effects.

In this trial, researchers are exploring the potential of pomegranate juice to slow or reverse increasing PSA levels in men who have undergone treatment for localized prostate cancer. Pomegranate juice is rich in phytochemicals, substances that have been shown in laboratory studies to inhibit cancer growth and spread. Men in this trial will be randomly assigned to drink a special preparation of pomegranate juice or a placebo drink daily for up to one year.

"In a phase II trial we conducted, daily consumption of pomegranate juice resulted in a significant lengthening of PSA doubling time and disease stabilization," said Dr. Pantuck. "We hope to verify those results in a phase III, double-blinded, placebo-controlled study."

Contact Information

See the lists of entry criteria and trial contact information or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for more information. The toll-free call is confidential.

  • Posted: September 25, 2007
  • Updated: March 16, 2010